S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

Madrigal Pharmaceuticals Stock Forecast, Price & News

-0.57 (-0.90%)
(As of 01/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
325,560 shs
Average Volume
193,957 shs
Market Capitalization
$1.08 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Madrigal Pharmaceuticals logo

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.


Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 3.2% Higher
January 10, 2022 |  americanbankingnews.com
3 Biotech Stocks With Major Catalysts in January
January 4, 2022 |  finance.yahoo.com
Madrigal Pharmaceuticals, Inc. (MDGL)
October 13, 2021 |  uk.finance.yahoo.com
Noteworthy Friday Option Activity: MDGL, GM, SWKS
September 24, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$15.52 per share


Net Income
$-202.24 million
Pretax Margin




Free Float
Market Cap
$1.08 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.45 out of 5 stars

Medical Sector

161st out of 1,415 stocks

Pharmaceutical Preparations Industry

65th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

Is Madrigal Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals
or view top-rated stocks.

How has Madrigal Pharmaceuticals' stock been impacted by COVID-19?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MDGL stock has decreased by 22.3% and is now trading at $63.00.
View which stocks have been most impacted by COVID-19

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Madrigal Pharmaceuticals

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) EPS for the quarter, topping the consensus estimate of ($3.87) by $0.08.
View Madrigal Pharmaceuticals' earnings history

What price target have analysts set for MDGL?

8 brokerages have issued 1-year target prices for Madrigal Pharmaceuticals' shares. Their forecasts range from $111.00 to $219.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $177.57 in the next twelve months. This suggests a possible upside of 181.9% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Paul A. Friedman, Chairman, President & Chief Executive Officer
  • Alex G. Howarth, Chief Financial Officer
  • Rebecca A. Taub, Director & President-Research & Development
  • Brian J. Lynch, Senior Vice President & General Counsel
  • Remy Sukhija, Chief Commercial Officer & Senior Vice President

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Shikiar Asset Management Inc. (0.06%), Liberty One Investment Management LLC (0.01%) and Cutler Group LP (0.00%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals

Which major investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Shikiar Asset Management Inc..
View insider buying and selling activity for Madrigal Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Liberty One Investment Management LLC, and Cutler Group LP.
View insider buying and selling activity for Madrigal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $63.00.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals has a market capitalization of $1.08 billion. The biopharmaceutical company earns $-202.24 million in net income (profit) each year or ($14.65) on an earnings per share basis.

How many employees does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals employs 42 workers across the globe.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Where are Madrigal Pharmaceuticals' headquarters?

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at [email protected], or via fax at 781-274-8228.

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.